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Division of Human Nutrition, Wageningen University, Wageningen, The NetherlandsSummary habits. An important determinant of lifestyle is diet. In thisNon-alcoholic fatty liver disease (NAFLD) is associated with the
growing incidence of metabolic syndrome. Diet is an important
contributor to the pathogenesis of NAFLD. In this review, we
focused on recent publications reporting on the effect of macro-
and micronutrients on development and progression of NAFLD.
In general, saturated fat and fructose seem to stimulate hepatic
lipid accumulation and progression into NASH, whereas unsatu-
rated fat, choline, antioxidants, and high-protein diets rich in
isoﬂavones seem to have a more preventive effect. Knowledge
of the underlying mechanisms by which diet affects NAFLD is
expanding, not in the least due to innovative techniques, such
as genomics tools that provide detailed comprehensive informa-
tion on a large high-throughput scale. Although most nutrients
seem to interfere with the balance between hepatic de novo lipo-
genesis (endogenous synthesis of fatty acids) and lipid oxidation
(burning fat for energy), there are also indications that diet can
trigger or prevent hepatic lipid accumulation by inﬂuencing the
interaction between liver, gut, and adipose tissue. This review
now gives a current detailed overview of diet-mediated mecha-
nisms underlying NAFLD development and progression and sum-
marizes recent results of genomics (transcriptomics, proteomics
and metabolomics) studies that contribute to improved staging,
monitoring and understanding of NAFLD pathophysiology.
 2012 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.Introduction
Metabolic syndrome is an emerging global epidemic, which com-
prises a cluster of metabolic disorders such as abdominal obesity
and insulin resistance. One of the other metabolic diseases often
associated with metabolic syndrome is non-alcoholic fatty liver
disease (NAFLD). NAFLD ranges from steatosis to non-alcoholic
steatohepatitis (NASH), with or without ﬁbrosis and cirrhosis.
The prevalence of NAFLD in Western society is 20–30% and the
probable increasing incidence of NAFLD can be linked to lifestyleJournal of Hepatology 20
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E-mail address: michael.muller@wur.nl (M. Müller).review, we summarize recent novel data on the effects of nutri-
ents and certain food bioactive compounds on development
and/or progression of NAFLD, and potentially also in prevention
of the disease. Potential underlying mechanisms are discussed
and summarized in Fig. 1. Moreover, this review discusses inno-
vative genomics techniques that are useful for improvement of
diagnosis and monitoring of NAFLD pathophysiology.Inﬂuence of nutrients on NAFLD
Fat
In NAFLD patients, a reduced intake of saturated fat that leads to
weight loss is linked to improved NAFLD pathophysiology.
Recently, it was also found that the ratio of polyunsaturated/sat-
urated fatty acid intake in NASH patients was lower than in the
healthy population [1]. In this association between saturated fat
and NASH, the intestinal incretin glucose-dependent insulino-
tropic polypeptide (GIP) seems to play an important role. NASH
patients exhibit a prolonged elevation of GIP after saturated fat
ingestion and this increased GIP response to saturated fat intake
is associated with the severity of liver disease (Fig. 1) [2]. Addi-
tionally, higher saturated fat intake seems to be correlated with
an impaired glutathione metabolism towards an oxidant status
in NASH patients [3]. Monounsaturated fatty acids (MUFA)
induce a more favorable plasma lipid proﬁle, with reduced oxi-
dized LDL, LDL cholesterol, triglycerides, and a lower total choles-
terol/HDL ratio [4]. Replacement of saturated fat in the diet by
MUFA to improve lipid proﬁles and thereby the health status is
still debated. In a recent review, it has been concluded that MUFA
in the diet can indeed be useful for NAFLD patients, but further
human studies are required to ascertain the beneﬁcial effect of
MUFA/olive oil on NAFLD [4].
Among polyunsaturated fatty acids (PUFA), in particular the
n-3 fatty acids seem to reduce the accumulation of triglycerides
and ameliorate hepatic steatosis [5]. Especially, docosahexaenoic
acids (DHA), which are long chain n-3 fatty acids, were found to
lower triglyceride levels in liver and improve the metabolic char-
acteristics of obesity in general. Mechanistically, MUFA and PUFA
might inﬂuence NAFLD by activation of peroxisome proliferator-
activated receptors (PPARs) and inhibition of transcription factor
sterol regulatory element binding protein-1 (SREBP-1) (Fig. 1).
Activation of PPARs stimulates lipid oxidation and decreases
inﬂammation and insulin resistance, leading to amelioration of
hepatic steatosis [5]. Inhibition of SREBP-1 can decrease the
expression of genes involved in hepatic de novo lipogenesis and12 vol. 57 j 1370–1373
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Fig. 1. Schematic overview of diet-induced mechanisms underlying the pathophysiology of NAFLD. Diet contributes to development and/or progression of NAFLD by
affecting several biological processes in the liver, but also in other peripheral organs like adipose tissue and intestine. The dashed lines indicate a correlation with NAFLD
progression, but the underlying mechanisms remain unclear.
JOURNAL OF HEPATOLOGYthereby reduce liver fat [5]. Supplementation of MUFA and/or
PUFA is currently investigated as a potential treatment against
NAFLD.
Carbohydrates
A recent study has shown that sucrose-sweetened beverages,
with a daily intake of 1 L, result in a higher relative amount of vis-
ceral adipose tissue (VAT), and liver fat accumulation than isoca-
loric semi-skim milk, aspartame-sweetened beverages, and water
[6]. Body weight and total fat mass are not signiﬁcantly different
between the four groups, indicating that sucrose has a primary
effect on expansion of VAT, including hepatic lipid accumulation.
A study comparing fructose-sweetened and glucose-sweetened
beverages revealed that mainly fructose-containing drinks
increase visceral adiposity and lipids in overweight subjects [7].
The mechanism behind the fructose-induced expansion of
ectopic fat is still under investigation, but it is hypothesized that
fructose is a strong inducer of de novo lipogenesis (Fig. 1). This is
supported by the fact that de novo lipogenesis only produces sat-
urated fatty acids and that in humans a fatty liver predominantlyJournal of Hepatology 2012exists of saturated fatty acids. Fructose consumption might
induce hepatic lipid accumulation by activating lipogenic gene
expression, but another explanation for its lipogenic nature
might be the direct ﬂow of fructose carbon into the glycolytic
pathway, bypassing a key regulatory enzyme of glycolysis, phos-
phofructokinase [8]. For this reason, a higher proportion of the
carbon from ingested fructose, as compared with glucose, is
metabolized into triglycerides. Fructose consumption can also
contribute to the inﬂammatory progression of NAFLD into NASH
by inducing bacterial overgrowth in the small intestine with a
concomitant increase in endotoxin levels in the portal vein
(Fig. 1) [9]. This might trigger the NASH pathology.
Protein
Until now, only a few human studies addressed protein intake
and intrahepatocellular lipids (IHCL) or NASH. Bortolotti et al.
have recently observed in sedentary obese women, that con-
sumed 60 g/day whey protein and were otherwise nourished on
a spontaneous diet, a 20% reduction in IHCL [10]. This change
was not related to changes in body weight or body composition.vol. 57 j 1370–1373 1371
Clinical Application of Basic Science
Rodent data more clearly demonstrate the hepatic and metabolic
adaptations to an increased dietary protein intake. In particular,
dietary whey and soy protein intake have been repetitively
shown to prevent or retard liver fat accumulation and NASH
[10,11].
Several mechanisms can explain the beneﬁcial effect of die-
tary protein on NAFLD (Fig. 1). As amino acid catabolism is an
energy requiring process, a high protein intake might trigger an
increased hepatic lipid oxidation through an increase in hepatic
energy expenditure. Secondly, taurine, a derivative of the amino
acid cysteine and a bile acid conjugate, is found to reduce hepatic
lipid accumulation and inﬂammation in animals by reducing ER-
stress associated with liver disease [12]. It is speculated that tau-
rine supplementation might serve as a preventative treatment for
NAFLD. Finally, amino acids or their metabolites can inﬂuence
hepatic metabolism by regulating the expression of numerous
metabolic genes. SREBP-1, bile acid-activated farnesoid X recep-
tor (FXR), adenosine monophosphate-activated protein kinase
and PPARc co-activator are important regulators of these diet-
induced changes in gene expression [13]. Interestingly, both the
involvement of taurine and FXR suggest that the protein-medi-
ated effect on NAFLD might be associated with bile acid
metabolism.
Micronutrients and other food components
Choline is an essential nutrient, mainly metabolized and stored in
the liver. Choline deﬁciency can affect NAFLD pathophysiology by
inducing abnormal phospholipid synthesis, defects in lipoprotein
secretion, oxidative damage due to mitochondrial dysfunction
and ER-stress [14]. It has been recently discovered that the individ-
ual requirement of choline to prevent liver dysfunction is depen-
dent on genetic variation and estrogen status [14]. Furthermore,
gut microbiota may inﬂuence bioavailability of dietary choline to
the host and thereby contribute to development of NAFLD [14].
An antioxidant that might be beneﬁcial to NAFLD is resvera-
trol. In animal studies, it was shown that resveratrol could reduce
hepatic oxidative stress and ameliorate NAFLD by inhibiting cyto-
kines and reducing fatty acid content, probably by stimulating
fatty acid oxidation [15]. Resveratrol has considerable potential
to improve NAFLD in humans, but one has to keep in mind that
substantial variation in metabolism between subjects affects
the bioavailability of resveratrol after consumption [15]. Addi-
tional human studies should demonstrate the potential protec-
tive effect of resveratrol on NAFLD.
Isoﬂavones are alsopotentially involved inNAFLDbecauseof its
abundant presence in soy protein and the reduction in liver fat
after soy intake [11]. The major soy isoﬂavones are genistin and
daidzin and most studies have been performed with one of these
components. Human intervention studies have not been reported
yet, but in most animal studies isoﬂavones improved NAFLD [16].
The underlying mechanism has been suggested to occur partly via
PPARs (fatty acid oxidation), carbohydrate responsive element
binding protein (lipogenesis) and anti-adipogenic Wnt signaling
[16].Phenotyping of NAFLD
There is a growing interest in the large potential of comprehen-
sive genomics tools for clinical purposes such as diagnosis,1372 Journal of Hepatology 2012staging, and monitoring of NAFLD. Using transcriptomics, proteo-
mics, and metabolomics, genome-wide changes can be assessed
on the level of transcriptome, proteome and metabolome, respec-
tively. Until now, most genomics studies are performed to opti-
mize or validate the usage of these less invasive tools for
appropriate application in monitoring NAFLD. However, genom-
ics tools are also highly valuable for studying the role of diet in
the NAFLD pathophysiology and unraveling the underlying
(molecular) mechanisms.
Transcriptomics
Transcriptomics, which employs microarray analysis to study
changes in messenger RNA expression, is a sensitive and well-
validated technique. Transcriptomics enables detection of small
diet-induced changes in gene expression and is an essential tech-
nique for human nutrigenomics studies [17]. Stefano et al.
recently analysed human liver biopsies from different stages of
NAFLD and found a progressively lower survivin expression in
advanced stages of NAFLD [18]. Transcriptomics studies to mech-
anistically unravel the effect of diet on NAFLD are mainly con-
ducted in mice, as human liver biopsies are scarce. Recently,
Duval et al. demonstrated an association between adipose tissue
dysfunction and NASH pathogenesis and identiﬁed several novel
potential predictive plasma biomarkers for NASH [19].
Proteomics
In humans, proteomics studies are mainly conducted to identify
novel biomarkers that facilitate accurate staging of NAFLD. Serum
proteomics identiﬁed ﬁbrinogen, RBP4, and lumican as biomarker
candidates to distinguish between simple steatosis, NASH, and
NASH with advanced ﬁbrosis [20]. By studying the underlying
mechanisms in animals, proteomics has recently revealed that
when a pronounced diet-induced hepatic accumulation of tri-
glycerides is visible, expression and cleavage of intermediate
microﬁlaments are increased [21]. Changes in keratin 8 and 18
and vimentin seemed to be linked to hepatic steatosis leading
to NASH. In line with these ﬁndings, Shen et al. found increased
serum levels of keratin 18 fragments in NAFLD and NASH
patients, probably due to enhanced proteolysis [22]. These frag-
ments could serve as novel human serum biomarkers.
Metabolomics
Metabolomics comprises the high-throughput quantiﬁcation and
characterization of small metabolites in tissues and bioﬂuids.
Recently, plasma metabolite proﬁles of subjects with NAFLD have
been compared to healthy controls. NAFLD patients showed
lower plasma levels of glutathione and higher levels of bile acids,
total carnitines, and c-glutamyl peptides [23]. Additionally, c-
glutamyl peptides were found to have the potential to discrimi-
nate between the different progression stages of NAFLD, making
it an interesting candidate biomarker. Comparison of metabolo-
mics results of mouse NAFLD models and patients in different
stages of NAFLD also showed a signiﬁcant overlap in serum
metabolites. In particular, the combination of glucose, lactate,
glutamate/glutamine and taurine was found to be indicative of
the risk of NAFLD progression [24].
One study combined transcriptomics, proteomics and meta-
bolomics to identify changes during high-fat diet-induced hepaticvol. 57 j 1370–1373
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steatosis [25]. Major changes were found in hepatic one-carbon
metabolism and pathways related to hepatic lipid accumulation.
In accordance with previously mentioned studies [23,24], they
also found a hepatic increase in taurine. These increased taurine
levels, together with changes in one-carbon metabolism could
reduce de novo glutathione synthesis, resulting in lower glutathi-
one levels, which is indicative of an increased ROS burden in diet-
induced hepatic steatosis. This study shows that the combination
of genomics tools facilitates the understanding of NAFLD
pathophysiology.
In conclusion, there is growing evidence that diet can affect
the pathophysiology of NAFLD. Saturated fat and fructose are
more likely to stimulate hepatic lipid accumulation and progres-
sion into NASH, whereas unsaturated fat, choline, antioxidants
and high-protein diets rich in isoﬂavones seem to have a more
preventive effect. However, whether speciﬁc dietary intervention
strategies with or without other changes in lifestyle (e.g., more
exercise) can also be used for treatment of NAFLD has still to
be proven. More human studies need to be performed and addi-
tional tools for monitoring and comprehensive phenotyping
NAFLD are essential, to extensively explore the potential role of
healthy dietary patterns for treatment of patients. Non-invasive
innovative high-throughput screening methods like genomics
tools are valuable techniques to gain more insight into the under-
lying mechanisms of the pathophysiology of NAFLD and to iden-
tify novel biomarkers, which solely, or even more likely in
combinations, can be used to distinguish the different stages of
NAFLD.Conﬂict of interest
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